Friday, July 10, 2026

Drug profile · INN

e7090

e7090 is a fibroblast growth factor receptor 1 inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — e7090
Class
Route
Patents
0
Programs
3
Data quality
0.70

Quick answer

e7090 is a fibroblast growth factor receptor 1 inhibitor.

Key facts

INN e7090
Mechanism Fibroblast growth factor receptor 1 inhibitor
Target Fibroblast growth factor receptor 1

Mechanism of action

Fibroblast growth factor receptor 1 inhibitor

Primary target: Fibroblast growth factor receptor 1

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. 09 Phase 3 · First People's Hospital · Acute Myeloid Leukaemia
  2. E7090 Phase 2 · Eisai · Cholangiocarcinoma
  3. P3C541b Lipopeptide Phase 1 · United Therapeutics Europe · HIV Infections

Related & competitor drugs

  1. pazopanib hydrochloride Vascular endothelial growth factor receptor inhibitor
  2. pemigatinib Antineoplastic and immunomodulating agents (L01)
  3. surufatinib Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is e7090?

e7090 is a fibroblast growth factor receptor 1 inhibitor.